Shopping Cart
- Remove All
Your shopping cart is currently empty
GSK-872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $30 | In Stock | |
| 5 mg | $68 | In Stock | |
| 10 mg | $116 | In Stock | |
| 25 mg | $188 | In Stock | |
| 50 mg | $321 | In Stock | |
| 100 mg | $493 | In Stock | |
| 200 mg | $706 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $74 | In Stock |
| Description | GSK-872 (GSK2399872A) is an effective and specific RIP3 kinase inhibitor. It binds RIP3 kinase domain with high affinity (IC50: 1.8 nM) and inhibits kinase activity (IC50: 1.3 nM). |
| Targets&IC50 | RIP3K:1.8 nM |
| In vitro | GSK872 (1 μM) has no inhibition for most of 300 human protein kinases tested. It fails to inhibit RIP1 kinase. In HT-29 cells, GSK872 concentration-dependently blocks TNF-induced necroptosis. In cell-based assays, there is a 100- to 1000-fold shift in the IC50 compared to the cell-free biochemical assays. GSK872 inhibits DAI- or TLR3-induced (RIP1-independent) death. It induces caspase activation and then induces apoptotic cell death[1]. |
| In vivo | In compared with no treatment after ischemic injury in vivo, GSK872 can significantly reduce HIF-1α expression [3]. |
| Synonyms | GSK'872, GSK872, GSK2399872A |
| Molecular Weight | 383.49 |
| Formula | C19H17N3O2S2 |
| Cas No. | 1346546-69-7 |
| Smiles | CC(C)S(=O)(=O)c1ccc2nccc(Nc3ccc4scnc4c3)c2c1 |
| Relative Density. | 1.395 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 141 mg/mL (367.68 mM), Sonication is recommended. Ethanol: 38 mg/mL (99.09 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.43 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.